This supports the hypothesis that, in patients at risk for cardiovascular disease such as hypertension, peripheral endothelial dysfunction extends to the bone marrow and may result in reduced NO bioavailability and, consequently, impaired MMP9-dependent (E)PC mobilization [11], [19]. The gene discussed is MMP9; the disease is Hypertension.